Financial Health Check: Examining Cara Therapeutics Inc (CARA)’s Key Ratios

Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Cara Therapeutics Inc (NASDAQ: CARA) closed the day trading at $0.28 up 12.33% from the previous closing price of $0.25. In other words, the price has increased by $12.33 from its previous closing price. On the day, 2.98 million shares were traded. CARA stock price reached its highest trading level at $0.3288 during the session, while it also had its lowest trading level at $0.2574.

Ratios:

For a better understanding of CARA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.38. In the meantime, Its Debt-to-Equity ratio is 1.52 whereas as Long-Term Debt/Eq ratio is at 1.52.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on June 13, 2024, Downgraded its rating to Hold and sets its target price to $1 from $6 previously.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’24 when Posner Christopher sold 3,936 shares for $0.75 per share. The transaction valued at 2,952 led to the insider holds 176,585 shares of the business.

Terrillion Scott sold 2,753 shares of CARA for $2,285 on Apr 05 ’24. The SEC’Y; CHIEF COMPLIANCE & G.C. now owns 88,247 shares after completing the transaction at $0.83 per share. On Apr 05 ’24, another insider, Goncalves Joana, who serves as the CHIEF MEDICAL OFFICER of the company, sold 2,753 shares for $0.83 each. As a result, the insider received 2,285 and left with 53,365 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARA now has a Market Capitalization of 15145253 and an Enterprise Value of -47582760. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.89 while its Price-to-Book (P/B) ratio in mrq is 0.51. Its current Enterprise Value per Revenue stands at -2.809 whereas that against EBITDA is 0.394.

Stock Price History:

The Beta on a monthly basis for CARA is 0.68, which has changed by -0.9145062 over the last 52 weeks, in comparison to a change of 0.26238096 over the same period for the S&P500. Over the past 52 weeks, CARA has reached a high of $4.45, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -59.09%, while the 200-Day Moving Average is calculated to be -71.13%.

Shares Statistics:

Over the past 3-months, CARA traded about 500.25K shares per day on average, while over the past 10 days, CARA traded about 1592910 shares per day. A total of 54.48M shares are outstanding, with a floating share count of 45.58M. Insiders hold about 16.63% of the company’s shares, while institutions hold 43.72% stake in the company. Shares short for CARA as of 1715731200 were 2443696 with a Short Ratio of 4.60, compared to 1713139200 on 2606185. Therefore, it implies a Short% of Shares Outstanding of 2443696 and a Short% of Float of 5.1999997.

Earnings Estimates

Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Cara Therapeutics Inc (CARA).On average, analysts expect EPS of -$0.27 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.35, while EPS last year was -$0.58. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.22 and low estimates of -$0.26.

Analysts are recommending an EPS of between -$1.12 and -$1.38 for the fiscal current year, implying an average EPS of -$1.28. EPS for the following year is -$0.81, with 5.0 analysts recommending between -$0.34 and -$1.13.

Revenue Estimates

5 analysts predict $1.17M in revenue for the current quarter. It ranges from a high estimate of $1.88M to a low estimate of $900k. As of the current estimate, Cara Therapeutics Inc’s year-ago sales were $6.93MFor the next quarter, 5 analysts are estimating revenue of $1.75M. There is a high estimate of $2.95M for the next quarter, whereas the lowest estimate is $900k.

A total of 5 analysts have provided revenue estimates for CARA’s current fiscal year. The highest revenue estimate was $9.94M, while the lowest revenue estimate was $4.8M, resulting in an average revenue estimate of $6.41M. In the same quarter a year ago, actual revenue was $20.97MBased on 5 analysts’ estimates, the company’s revenue will be $6.79M in the next fiscal year. The high estimate is $12.55M and the low estimate is $3.12M.

Most Popular